Back to Search
Start Over
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma
- Source :
- International Journal of Clinical Oncology. 24:1311-1319
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS. We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan–Meier method and the log-rank test were used for survival analyses. Median age of the patients was 61.5 years (range 25–79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327). The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
Extraskeletal Osteosarcoma
medicine.medical_treatment
Bone Neoplasms
Soft Tissue Neoplasms
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Doxorubicin
Ifosfamide
Aged
Retrospective Studies
Osteosarcoma
Chemotherapy
business.industry
Wide local excision
Soft tissue sarcoma
Hematology
General Medicine
Middle Aged
Prognosis
medicine.disease
Neoadjuvant Therapy
Survival Rate
Regimen
030104 developmental biology
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Female
Surgery
business
medicine.drug
Subjects
Details
- ISSN :
- 14377772 and 13419625
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- International Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....10e8d7704f084503bab3d0b0858c4f58